RDY
Dr. Reddy's Laboratories Ltd. Sponsored ADR · NYSE
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website drreddys.com
- Employees(FY) 25863
- ISIN US2561352038
Performance
-3.18%
1W
-10.25%
1M
-13.62%
3M
+5.27%
6M
+3.27%
YTD
+6.46%
1Y
Profile
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Technical Analysis of RDY 2024-11-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-07 06:31
- 2024-11-06 09:56
- 2024-11-06 02:15
- 2024-11-05 14:23
Analyst Report: Dr. Reddy's Laboratories Limited(Morningstar Research)
- 2024-11-05 09:59
Dr. Reddy’s Q2 & H1FY25 Financial Results(Business Wire)
- 2024-11-04 20:59
Dr. Reddys Q2 & H1FY25 Financial Results(Businesswire)
- 2024-10-29 19:59
Analyst Report: Dr. Reddy's Laboratories Limited(Morningstar Research)
- 2024-10-25 07:40
- 2024-10-24 19:40
- 2024-10-14 09:47
- 2024-10-13 21:47
- 2024-10-09 07:57
- 2024-10-09 03:58
- 2024-10-08 11:32
- 2024-10-08 06:27
- 2024-10-07 23:32
- 2024-10-02 11:10
- 2024-10-01 23:10
- 2024-10-01 07:14
- 2024-09-28 00:57
Dr. Reddys Expands Portfolio with $620M Investment(Yahoo Finance)
- 2024-08-21 06:13
Dr Reddy’s, Aurigene and Kainomyx to co-develop anti-malarials(Pharmaceutical Technology)
- 2024-08-20 14:42
- 2024-08-20 02:42
- 2024-07-29 13:01
Analyst Report: Dr. Reddy's Laboratories Limited(Morningstar Research)
- 2024-07-29 11:55
- 2024-07-29 10:07
- 2024-07-28 23:55
- 2024-07-27 09:51
Dr. Reddy’s Q1FY25 Financial Results(Business Wire)
- 2024-07-26 21:51
Dr. Reddys Q1FY25 Financial Results(Businesswire)
- 2024-06-26 22:25
Page 1 of 6
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.